CFQ175
Total Payments
$48,606
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $48,606 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $48,606 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CSJ148 COMPARED TO PLACEBO TO PREVENT HUMAN CYTOMEGALOVIRUS HCMV REPLICATION IN STEM CELL TRANSPLANT PATIENTS | Novartis Pharmaceuticals Corporation | $40,940 | 0 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED SINGLE ASCENDING DOSE FIRST IN HUMAN STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF CFZ533 IN HEALTHY SUBJECTS AND RHEUMATOID ARTHRITIS PATIENTS | Novartis Pharmaceuticals Corporation | $7,667 | 0 |
Top Doctors Receiving Payments for CFQ175
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Duncansville, PA | $48,606 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $48,606
- Total Doctors 0
- Transactions 3
About CFQ175
CFQ175 is a drug associated with $48,606 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2017. In 2017, $48,606 was paid across 3 transactions to 0 doctors.
The most common payment nature for CFQ175 is "Unspecified" ($48,606, 100.0% of total).
CFQ175 is associated with 2 research studies, including "A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CSJ148 COMPARED TO PLACEBO TO PREVENT HUMAN CYTOMEGALOVIRUS HCMV REPLICATION IN STEM CELL TRANSPLANT PATIENTS" ($40,940).